| Cyclophosphamide therapy for MS. | |
| | |
MedLine Citation:
|
PMID: 16417815 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cyclophosphamide has been widely studied for the treatment of MS and the effective stabilization of selected patients on therapy has been suggested in several studies. This drug has selective effects on the immune response, such as suppression of helper Th1 activity and enhancement of helper Th2 responses; both of these processes are thought to be involved in the beneficial effect of cyclophosphamide in MS. Over the years, especially with the advent of magnetic resonance imaging (MRI), there has been an improved understanding of the profound anti-inflammatory effect of cyclophosphamide, evidenced by its effect on clinical relapses and contrast-enhancing lesions on MRI. Toxic effects on the bladder and the risk of malignancy prevent the widespread use of cyclophosphamide in early MS; however, it can be dosed safely and is usually well tolerated in actively progressing relapsing-remitting or early secondary progressive MS cases that are unresponsive to beta interferon and glatiramer acetate. |
| | |
Authors:
|
S A Gauthier; H L Weiner |
Related Documents
:
|
2449335 - Brain-stem auditory evoked potentials (baeps) and magnetic resonance imaging (mri) in a... 17851455 - Acute astrocyte activation in brain detected by mri: new insights into t(1) hypointensity. 11724445 - Modelling new enhancing mri lesion counts in multiple sclerosis. 16012595 - Whole-head squid system in a superconducting magnetic shield. 10494345 - Assessment of brain tissue viability under clinical circumstances. 15226085 - Cerebello-pontine angle (cpa) lymphoma with perineural extension into the middle fossa:... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International MS journal / MS Forum Volume: 12 ISSN: 1352-8963 ISO Abbreviation: Int MS J Publication Date: 2005 Aug |
Date Detail:
|
Created Date: 2006-01-18 Completed Date: 2006-03-15 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9804403 Medline TA: Int MS J Country: England |
Other Details:
|
Languages: eng Pagination: 52-8 Citation Subset: IM |
Affiliation:
|
Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Brain / pathology Cyclophosphamide / administration & dosage, adverse effects, therapeutic use* Humans Immunosuppressive Agents / administration & dosage, adverse effects, therapeutic use* Injections, Intravenous Middle Aged Multiple Sclerosis / drug therapy*, pathology Randomized Controlled Trials as Topic |
| Chemical | |
Reg. No./Substance:
|
0/Immunosuppressive Agents; 50-18-0/Cyclophosphamide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Neurodegeneration and clinical relevance for early treatment in multiple sclerosis.
Next Document: Managing specific symptoms in people with multiple sclerosis.